(Q37797460)

23 August 2017

Sunitinib for metastatic renal cell carcinoma (English)

1 reference

23 August 2017

3

Lisa Pickering

1 reference

23 August 2017

Deborah Mukherji

1

1 reference

PubMed ID

20919823

23 August 2017

James Larkin

series ordinal

2

1 reference

PubMed ID

20919823

23 August 2017

language of work or name

English

0 references

publication date

1 September 2010

1 reference

23 August 2017

1 reference

23 August 2017

6

1 reference

23 August 2017

9

1 reference

23 August 2017

1377-1385

1 reference

23 August 2017

1 reference

Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease

21 January 2018

1 reference

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial

21 January 2018

1 reference

Identification of the von Hippel-Lindau disease tumor suppressor gene

21 January 2018

1 reference

Mutations of the VHL tumour suppressor gene in renal carcinoma

21 January 2018

1 reference

Role of VHL gene mutation in human cancer

21 January 2018

1 reference

mTOR and cancer: insights into a complex relationship

21 January 2018

1 reference

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

21 January 2018

1 reference

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

21 January 2018

1 reference

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma

21 January 2018

1 reference

The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels

21 January 2018

1 reference

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

21 January 2018

1 reference

A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period

21 January 2018

1 reference

Improving cancer outcomes through international collaboration in academic cancer treatment trials

21 January 2018

1 reference

Pharmacokinetics of sunitinib malate in subjects with hepatic impairment

21 January 2018

1 reference

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

Sunitinib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial

21 January 2018

1 reference

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

21 January 2018

1 reference

The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation

21 January 2018

1 reference

Shrinkage of thyroid volume in sunitinib-treated patients with renal-cell carcinoma: a potential marker of irreversible thyroid dysfunction?

21 January 2018

1 reference

Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis

21 January 2018

1 reference

Sunitinib in solid tumors

21 January 2018

1 reference

Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

21 January 2018

1 reference

Combination systemic therapy for advanced renal cell carcinoma

21 January 2018

1 reference

Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma

21 January 2018

1 reference

Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.

21 January 2018

1 reference

Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma

21 January 2018

1 reference

Biomarkers of response and resistance to antiangiogenic therapy

21 January 2018

1 reference

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

21 January 2018

1 reference

CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies.

21 January 2018

1 reference

Surrogate biomarkers in evaluating response to anti-angiogenic agents: focus on sunitinib

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FON.10.94

1 reference

23 August 2017

1 reference

PubMed ID

20919823